Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

A. Cuneo, AR. Mato, GM. Rigolin, A. Piciocchi, M. Gentile, L. Laurenti, JN. Allan, JM. Pagel, DM. Brander, BT. Hill, A. Winter, N. Lamanna, CS. Tam, R. Jacobs, F. Lansigan, PM. Barr, M. Shadman, AP. Skarbnik, JJ. Pu, AR. Sehgal, SJ. Schuster, NN....

. 2020 ; 9 (22) : 8468-8479. [pub] 20200924

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026437

Grantová podpora
P30 CA008748 NCI NIH HHS - United States

Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real-world patients and performed a matched adjusted indirect comparison with a cohort of patients treated with ibrutinib. One hundred and fifty-seven patients with creatinine clearance (CrCl) <70 mL/min and/or CIRS score >6 were treated with BR. The median age was 72 years; 69% of patients had ≥2 comorbidities and the median CrCl was 59.8 mL/min. 17.6% of patients carried TP53 disruption. The median progression-free survival (PFS) was 45 months; TP53 disruption was associated with a shorter PFS (P = 0.05). The overall survival (OS) at 12, 24, and 36 months was 96.2%, 90.1%, and 79.5%, respectively. TP53 disruption was associated with an increased risk of death (P = 0.01). Data on 162 patients ≥65 years treated with ibrutinib were analyzed and compared with 165 patients ≥65 years treated with BR. Factors predicting for a longer PFS at multivariable analysis in the total patient population treated with BR and ibrutinib were age (HR 1.06, 95% CI 1.02-1.10, P < 0.01) and treatment with ibrutinib (HR 0.55, 95% CI 0.33-0.93, P = 0.03). In a post hoc analysis of patients in advanced stage, a significant PFS advantage was observed in patient who had received ibrutinib (P = 0.03), who showed a trend for OS advantage (P = 0.08). We arrived at the following conclusions: (a) BR is a relatively effective first-line regimen in a real-world population of unfit patients without TP53 disruption, (b) ibrutinib provided longer disease control than BR in patients with advanced disease stage.

Catania Università di Catania Cattedra di Ematologia Catania Italy

Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute Seattle WA USA

Columbia University Medical Center New York NY USA

Dartmouth Hitchcock Medical Center Lebanon NH USA

Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute Carolinas Healthcare System Charlotte NC USA

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Medicine Department of Hematology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Onco Hematology Hematology Unit A O of Cosenza Cosenza Italy

Department of Radiological Radiotherapeutic and Hematological Sciences Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Department of Translational and Precision Medicine University La Sapienza UOC di Ematologia con Trapianto Ospedale S Maria Goretti Latina Italy

Division of Hematologic Malignancies and Cellular Therapy Duke University Durham NC USA

Division of Hematological Oncology CLL Program Memorial Sloan Kettering Cancer Center New York NY USA

Division of Hematology A O U Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy

Division of Hematology and Oncology Medical College of Wisconsin Milwaukee WI USA

Division of Hematology and Oncology University of Pennsylvania Philadelphia PA USA

Division of Hematology Department of Translational Medicine University of eastern Piedmont Novara Italy

Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Seattle WA USA

Hematology and Clinical Immunology Department of Medicine University of Padua Padua Italy

Hematology and Transplant Unit San Maurizio Hospital Azienda Sanitaria dell'Alto Adige Bolzano Italy

Hematology Azienda USL IRCCS Reggio Emilia Italy

Hematology Department Fondazione IRCCS Istituto Nazionale Tumori Milano Italy

Hematology Department of Cell Therapy and Hematology University Hospital Verona Italy

Hematology Department of Medical Sciences St Anna University Hospital Ferrara Italy

Hematology Department of Translational and Precision Medicine Sapienza University Rome Italy

Hematology Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy

Hematology Unit A Pugliese Hospital Azienda Ospedaliera Pugliese Ciaccio Catanzaro Italy

Hematology Unit Hospital Universitario Madrid Spain

Hematology Unit IRCCS Policlinico San Matteo Pavia Italy

Hospital Costa del Sol Marbella Spain

Italian Group for Adult Hematologic Diseases Data Center and Health Outcomes Research Unit Rome Italy

Lymphoproliferative Disorders Program Novant Health Cancer Institute Charlotte NC USA

Oncology Unit Cardinal Massaia Hospital Asti Italy

Peter McCallum Cancer Centre University of Melbourne Melbourne Victoria Australia

Strategic Research Program on CLL Division of Experimental Oncology IRCCS Ospedale San Raffaele Università Vita Salute San Raffaele Milan Italy

SUNY Upstate Medical University SUNY Upstate Medical University Syracuse NY USA

Taussig Cancer Institute Cleveland Clinic Cleveland OH USA

University of Pittsburgh Pittsburgh PA USA

Weill Cornell Medicine New York NY USA

Wilmot Cancer Institute University of Rochester Medical Center Rochester NY USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026437
003      
CZ-PrNML
005      
20240516083903.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.3470 $2 doi
035    __
$a (PubMed)32969597
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cuneo, Antonio $u Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy
245    10
$a Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study / $c A. Cuneo, AR. Mato, GM. Rigolin, A. Piciocchi, M. Gentile, L. Laurenti, JN. Allan, JM. Pagel, DM. Brander, BT. Hill, A. Winter, N. Lamanna, CS. Tam, R. Jacobs, F. Lansigan, PM. Barr, M. Shadman, AP. Skarbnik, JJ. Pu, AR. Sehgal, SJ. Schuster, NN. Shah, CS. Ujjani, L. Roeker, EM. Orlandi, A. Billio, L. Trentin, M. Spacek, M. Marchetti, A. Tedeschi, F. Ilariucci, G. Gaidano, M. Doubek, L. Farina, S. Molica, F. Di Raimondo, M. Coscia, FR. Mauro, J. de la Serna, A. Medina Perez, I. Ferrarini, G. Cimino, M. Cavallari, R. Cucci, M. Vignetti, R. Foà, P. Ghia, GIMEMA, European Research Initiative (ERIC) on CLL, US study group
520    9_
$a Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real-world patients and performed a matched adjusted indirect comparison with a cohort of patients treated with ibrutinib. One hundred and fifty-seven patients with creatinine clearance (CrCl) <70 mL/min and/or CIRS score >6 were treated with BR. The median age was 72 years; 69% of patients had ≥2 comorbidities and the median CrCl was 59.8 mL/min. 17.6% of patients carried TP53 disruption. The median progression-free survival (PFS) was 45 months; TP53 disruption was associated with a shorter PFS (P = 0.05). The overall survival (OS) at 12, 24, and 36 months was 96.2%, 90.1%, and 79.5%, respectively. TP53 disruption was associated with an increased risk of death (P = 0.01). Data on 162 patients ≥65 years treated with ibrutinib were analyzed and compared with 165 patients ≥65 years treated with BR. Factors predicting for a longer PFS at multivariable analysis in the total patient population treated with BR and ibrutinib were age (HR 1.06, 95% CI 1.02-1.10, P < 0.01) and treatment with ibrutinib (HR 0.55, 95% CI 0.33-0.93, P = 0.03). In a post hoc analysis of patients in advanced stage, a significant PFS advantage was observed in patient who had received ibrutinib (P = 0.03), who showed a trend for OS advantage (P = 0.08). We arrived at the following conclusions: (a) BR is a relatively effective first-line regimen in a real-world population of unfit patients without TP53 disruption, (b) ibrutinib provided longer disease control than BR in patients with advanced disease stage.
650    _2
$a adenin $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D000225
650    _2
$a senioři $7 D000368
650    _2
$a alkylační protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D018906
650    _2
$a protinádorové látky imunologicky aktivní $x škodlivé účinky $x terapeutické užití $7 D000074322
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a bendamustin hydrochlorid $x škodlivé účinky $x terapeutické užití $7 D000069461
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a piperidiny $x škodlivé účinky $x terapeutické užití $7 D010880
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $x terapeutické užití $7 D047428
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rituximab $x škodlivé účinky $x terapeutické užití $7 D000069283
650    _2
$a časové faktory $7 D013997
651    _2
$a Evropa $7 D005060
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mato, Anthony R $u Division of Hematological Oncology, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Rigolin, Gian Matteo $u Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy
700    1_
$a Piciocchi, Alfonso $u Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy
700    1_
$a Gentile, Massimo $u Department of Onco-Hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
700    1_
$a Laurenti, Luca $u Department of Radiological, Radiotherapeutic and Hematological Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
700    1_
$a Allan, John N $u Weill Cornell Medicine, New York, NY, USA
700    1_
$a Pagel, John M $u Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA
700    1_
$a Brander, Danielle M $u Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA
700    1_
$a Hill, Brian T $u Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Winter, Allison $u Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Lamanna, Nicole $u Columbia University Medical Center, New York, NY, USA
700    1_
$a Tam, Constantine S $u Peter McCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
700    1_
$a Jacobs, Ryan $u Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA
700    1_
$a Lansigan, Frederick $u Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
700    1_
$a Barr, Paul M $u Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
700    1_
$a Shadman, Mazyar $u Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA
700    1_
$a Skarbnik, Alan P $u Lymphoproliferative Disorders Program, Novant Health Cancer Institute, Charlotte, NC, USA
700    1_
$a Pu, Jeffrey J $u SUNY Upstate Medical University, SUNY Upstate Medical University, Syracuse, NY, USA
700    1_
$a Sehgal, Alison R $u University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Schuster, Stephen J $u Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Shah, Nirav N $u Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
700    1_
$a Ujjani, Chaitra S $u Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA
700    1_
$a Roeker, Lindsey $u Division of Hematological Oncology, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Orlandi, Ester Maria $u Hematology Unit, IRCCS Policlinico San Matteo, Pavia, Italy
700    1_
$a Billio, Atto $u Hematology and Transplant Unit, San Maurizio Hospital, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy
700    1_
$a Trentin, Livio $u Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padua, Italy
700    1_
$a Spacek, Martin $u Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Marchetti, Monia $u Oncology Unit, Cardinal Massaia Hospital, Asti, Italy
700    1_
$a Tedeschi, Alessandra $u Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
700    1_
$a Ilariucci, Fiorella $u Hematology, Azienda USL-IRCCS, Reggio Emilia, Italy
700    1_
$a Gaidano, Gianluca $u Division of Hematology, Department of Translational Medicine, University of eastern Piedmont, Novara, Italy
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Farina, Lucia $u Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
700    1_
$a Molica, Stefano $u Hematology Unit, A. Pugliese Hospital, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy
700    1_
$a Di Raimondo, Francesco $u Catania Università di Catania, Cattedra di Ematologia, Catania, Italy
700    1_
$a Coscia, Marta $u Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
700    1_
$a Mauro, Francesca Romana $u Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy
700    1_
$a de la Serna, Javier $u Hematology Unit, Hospital Universitario, Madrid, Spain
700    1_
$a Medina Perez, Angeles $u Hospital Costa del Sol, Marbella, Spain
700    1_
$a Ferrarini, Isacco $u Hematology, Department of Cell Therapy and Hematology, University Hospital, Verona, Italy
700    1_
$a Cimino, Giuseppe $u Department of Translational and Precision Medicine, University "La Sapienza", UOC di Ematologia con Trapianto, Ospedale S. Maria Goretti, Latina, Italy
700    1_
$a Cavallari, Maurizio $u Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy
700    1_
$a Cucci, Rosalba $u Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy
700    1_
$a Vignetti, Marco $u Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy
700    1_
$a Foa, Robin $u Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy $7 xx0317383
700    1_
$a Ghia, Paolo $u Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy
710    2_
$a GIMEMA, European Research Initiative (ERIC) on CLL, US study group
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 9, č. 22 (2020), s. 8468-8479
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32969597 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240516083857 $b ABA008
999    __
$a ok $b bmc $g 1715225 $s 1146944
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 22 $d 8468-8479 $e 20200924 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace